Human Glypican-3 Protein (C-His)

Cat # Size Price Quantity
80200125 ug$145
802002100 ug$295

Product Details


ApplicationELISA, BLI
FormatLiquid, Purified
Expression HostCHO
Target NameGPC3, GTR2-2, MXR7, SDYS, OCI5,
SpeciesHuman
SourcesHuman Glypican-3 (Gln25-His559) with C-terminus His tag is expressed in CHO cells
accession numberP51654
Molecular WeightThe protein has a predicted molecular weight of 62kDa. Under DTT-reducing conditions, it migrates at approximately 65-100 kDa on SDS-PAGE.
Affinity TagC-His
Purity>95% based on SDS-PAGE under reducing condition
Formulation1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin levelNot tested
Protein Concentration25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and HandlingBriefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

Background Information


Glypicans are heparan sulfate proteoglycans anchored to the cell surface by a glycosyl-phosphatidylinositol (GPI) linkage. There are six known mammalian glypicans (GPC1 to GPC6), which can be released by the lipase Notum. They regulate signaling pathways like Wnt, Hedgehog, FGF, and BMPs. Glypican-3 (GPC3) plays a role in modulating IGF2 interactions and influences cell proliferation. It also interacts with FGF-basic via heparan sulfate chains. Mutations in GPC3 cause Simpson-Golabi-Behmel Syndrome (SGBS), leading to overgrowth, dysmorphism, and malformations. GPC3 is expressed as a 70 kDa precursor, cleaved into a 40 kDa N-terminal and 30 kDa C-terminal subunit. It is highly expressed in Hepatocellular carcinoma and melanoma, but downregulated in cancers like ovarian, cholangiocarcinoma, mesothelioma, and breast cancer due to promoter hypermethylation.